Acute myeloid leukemia (AML) is a systemic disease that is metastatic from diagnosis; therefore, the problems typically associated with local and regional control, i.e., those associated with surgery and radiation therapy, do not play a role. Since virtually all patients who die as a result of a malignant disease die of systemic (metastatic) cancer, AML has served as a prototype illness for the development of systemic therapies, and advances in the control of this disease have been rapidly applied to the control of the more common metastatic cancers in man.
CITATION STYLE
Freireich, E. J. (2013). Acute myeloid leukemia. In 60 Years of Survival Outcomes at the University of Texas MD Anderson Cancer Center (Vol. 9781461451976, pp. 205–209). Springer New York. https://doi.org/10.1007/978-1-4614-5197-6_19
Mendeley helps you to discover research relevant for your work.